These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 25468170)

  • 21. Amoxicillin plus clavulanic acid versus appendicectomy for treatment of acute uncomplicated appendicitis: an open-label, non-inferiority, randomised controlled trial.
    Vons C; Barry C; Maitre S; Pautrat K; Leconte M; Costaglioli B; Karoui M; Alves A; Dousset B; Valleur P; Falissard B; Franco D
    Lancet; 2011 May; 377(9777):1573-9. PubMed ID: 21550483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.
    Kaasch AJ; López-Cortés LE; Rodríguez-Baño J; Cisneros JM; Dolores Navarro M; Fätkenheuer G; Jung N; Rieg S; Lepeule R; Coutte L; Bernard L; Lemaignen A; Kösters K; MacKenzie CR; Soriano A; Hagel S; Fantin B; Lafaurie M; Talarmin JP; Dinh A; Guimard T; Boutoille D; Welte T; Reuter S; Kluytmans J; Martin ML; Forestier E; Stocker H; Vitrat V; Tattevin P; Rommerskirchen A; Noret M; Adams A; Kern WV; Hellmich M; Seifert H;
    Lancet Infect Dis; 2024 May; 24(5):523-534. PubMed ID: 38244557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns).
    Stocker M; van Herk W; El Helou S; Dutta S; Fontana MS; Schuerman FABA; van den Tooren-de Groot RK; Wieringa JW; Janota J; van der Meer-Kappelle LH; Moonen R; Sie SD; de Vries E; Donker AE; Zimmerman U; Schlapbach LJ; de Mol AC; Hoffman-Haringsma A; Roy M; Tomaske M; Kornelisse RF; van Gijsel J; Visser EG; Willemsen SP; van Rossum AMC;
    Lancet; 2017 Aug; 390(10097):871-881. PubMed ID: 28711318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.
    Baulac M; Brodie MJ; Patten A; Segieth J; Giorgi L
    Lancet Neurol; 2012 Jul; 11(7):579-88. PubMed ID: 22683226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
    Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
    Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE).
    Healey JS; Hohnloser SH; Glikson M; Neuzner J; Mabo P; Vinolas X; Kautzner J; O'Hara G; VanErven L; Gadler F; Pogue J; Appl U; Gilkerson J; Pochet T; Stein KM; Merkely B; Chrolavicius S; Meeks B; Foldesi C; Thibault B; Connolly SJ;
    Lancet; 2015 Feb; 385(9970):785-91. PubMed ID: 25715991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
    Arribas JR; Girard PM; Landman R; Pich J; Mallolas J; Martínez-Rebollar M; Zamora FX; Estrada V; Crespo M; Podzamczer D; Portilla J; Dronda F; Iribarren JA; Domingo P; Pulido F; Montero M; Knobel H; Cabié A; Weiss L; Gatell JM;
    Lancet Infect Dis; 2015 Jul; 15(7):785-92. PubMed ID: 26062880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial.
    Bowen AC; Tong SY; Andrews RM; O'Meara IM; McDonald MI; Chatfield MD; Currie BJ; Carapetis JR
    Lancet; 2014 Dec; 384(9960):2132-40. PubMed ID: 25172376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
    Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
    Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Day-patient treatment after short inpatient care versus continued inpatient treatment in adolescents with anorexia nervosa (ANDI): a multicentre, randomised, open-label, non-inferiority trial.
    Herpertz-Dahlmann B; Schwarte R; Krei M; Egberts K; Warnke A; Wewetzer C; Pfeiffer E; Fleischhaker C; Scherag A; Holtkamp K; Hagenah U; Bühren K; Konrad K; Schmidt U; Schade-Brittinger C; Timmesfeld N; Dempfle A
    Lancet; 2014 Apr; 383(9924):1222-9. PubMed ID: 24439238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial.
    Hill LF; Clements MN; Turner MA; Donà D; Lutsar I; Jacqz-Aigrain E; Heath PT; Roilides E; Rawcliffe L; Alonso-Diaz C; Baraldi E; Dotta A; Ilmoja ML; Mahaveer A; Metsvaht T; Mitsiakos G; Papaevangelou V; Sarafidis K; Walker AS; Sharland M;
    Lancet Child Adolesc Health; 2022 Jan; 6(1):49-59. PubMed ID: 34843669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial.
    Ibrahim LF; Hopper SM; Orsini F; Daley AJ; Babl FE; Bryant PA
    Lancet Infect Dis; 2019 May; 19(5):477-486. PubMed ID: 30853250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
    Malfertheiner P; Bazzoli F; Delchier JC; Celiñski K; Giguère M; Rivière M; Mégraud F;
    Lancet; 2011 Mar; 377(9769):905-13. PubMed ID: 21345487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is switching to an oral antibiotic regimen safe after 2 weeks of intravenous treatment for primary bacterial vertebral osteomyelitis?
    Babouee Flury B; Elzi L; Kolbe M; Frei R; Weisser M; Schären S; Widmer AF; Battegay M
    BMC Infect Dis; 2014 Apr; 14():226. PubMed ID: 24767169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
    Eron JJ; Young B; Cooper DA; Youle M; Dejesus E; Andrade-Villanueva J; Workman C; Zajdenverg R; Fätkenheuer G; Berger DS; Kumar PN; Rodgers AJ; Shaughnessy MA; Walker ML; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Xu X; Sklar P;
    Lancet; 2010 Jan; 375(9712):396-407. PubMed ID: 20074791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pyogenic vertebral osteomyelitis: identification of microorganism and laboratory markers used to predict clinical outcome.
    Yoon SH; Chung SK; Kim KJ; Kim HJ; Jin YJ; Kim HB
    Eur Spine J; 2010 Apr; 19(4):575-82. PubMed ID: 19937064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.